Halozyme CEO Helen Torley Exercises Options, Sells Shares

What Happened

• Helen Torley, President & CEO (and director) of Halozyme Therapeutics (HALO), exercised 60,000 stock options (20,000 shares each on Aug 17, 18 and 19, 2026) at a strike price of $18.41 and immediately sold the 60,000 resulting shares in open-market transactions.
• The exercises cost $368,200 each day (total exercise cost $1,104,600). The 60,000 shares sold generated gross proceeds of approximately $6,275,593 (sales executed across Aug 17–19, 2026). These transactions are coded M (option exercise) and S (sale).

Key Details

• Transaction dates: Aug 17, 18 and 19, 2026.
• Options exercised: 3 × 20,000 = 60,000 shares at $18.41 (each exercise = $368,200; total = $1,104,600).
• Shares sold (open market): 60,000 shares across the three dates; gross sale proceeds ≈ $6,275,593.
• Sale price range: individual trades reported between about $98.58 and $107.90 per share (see footnotes for weighted-average ranges per trade group).
• Notable footnotes: Trades were executed pursuant to a written Rule 10b5-1 trading plan adopted Dec 3, 2025. The shares sold were acquired following exercise of options with a ten‑year term expiring Feb 2028; the options were originally granted Feb 14, 2018 (standard multi‑year vesting noted).
• Post-transaction holdings: the filing excerpt provided does not state Torley’s total shares held after these transactions.
• Timeliness: Form 4 was filed on Aug 19, 2026 covering the Aug 17–19 transactions (no late‑filing flag indicated in the provided data).

Context

• These transactions are effectively a cashless exercise: Torley converted vested options into shares at $18.41 and sold those shares in the open market the same days. That pattern is commonly used to cover exercise costs and taxes rather than to signal a change in view on the company.
• The presence of a 10b5‑1 plan indicates the sales were prearranged when the plan was adopted; such plans are intended to remove discretionary timing by the insider.